NCT05277480View on ClinicalTrials.gov

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

November 26, 2023

Conditions
Effect of DrugDrugToxicity
Interventions
DRUG

Apatinib+IE

apatinib po； ifosfamide ivgtt ; etoposide ivgtt .

DRUG

IE

ifosfamide ivgtt ; etoposide ivgtt .

Trial Locations (5)

100044

Peking University People's Hospital, Beijing

Unknown

Peking University People's Hospital, Beijing

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing

Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Peking University People's Hospital

OTHER